Literature DB >> 31862313

Population pharmacokinetic study of tacrolimus in pediatric patients with primary nephrotic syndrome: A comparison of linear and nonlinear Michaelis-Menten pharmacokinetic model.

Lingfei Huang1, Yixi Liu2, Zheng Jiao3, Junyan Wang1, Luo Fang1, Jianhua Mao4.   

Abstract

BACKGROUND: Little is known about the population pharmacokinetics (PPK) of tacrolimus (TAC) in pediatric patients with primary nephrotic syndrome (PNS). In this study, we aimed to compare the predictive performance between nonlinear and linear PK models and investigate the significant factors influencing TAC PK characteristics in pediatric PNS.
METHODS: Data were obtained from 71 pediatric patients with PNS, along with 525 TAC trough concentrations at steady-state. Patients' demographic, medical, and treatment details were collected. Genetic polymorphisms of CYP3A4*1G, CYP3A5*3, and ABCB1-C3435T were analyzed. The PPK models were developed using nonlinear mixed-effects model (NONMEM®) software. Two modeling strategies, linear compartmental and nonlinear Michaelis-Menten (MM) models, were evaluated and compared.
RESULTS: Body weight, age, daily dose of TAC, co-therapy drugs (including azole antifungal agents and diltiazem), and CYP3A5*3 genotype were the important factors in the final linear model (one-compartment model), whereas only body weight, co-therapy drugs, and CYP3A5*3 genotype were the important factors in the final nonlinear MM model. Apparent clearance and volume of distribution in the final linear model were 7.13 L/h and 142 L, respectively. The maximal dose rate (Vmax) of the nonlinear MM model was 1.92 mg/day and the average concentration at steady-state at half-Vmax (Km) was 1.98 ng/mL. The nonlinear model described the data better than the linear model. Dosing regimens were proposed based on the nonlinear PK model.
CONCLUSION: Our findings demonstrated that the nonlinear MM model showed better predictive performance than the linear compartmental model, providing reliable support for optimizing TAC dosing and adjustment in children with PNS.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Children; Nonlinear pharmacokinetics; Population pharmacokinetic; Primary nephrotic syndrome; Tacrolimus

Mesh:

Substances:

Year:  2019        PMID: 31862313     DOI: 10.1016/j.ejps.2019.105199

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  4 in total

1.  Population Pharmacokinetics and Initial Dosage Optimization of Tacrolimus in Pediatric Hematopoietic Stem Cell Transplant Patients.

Authors:  Xiao-Lin Liu; Yan-Ping Guan; Ying Wang; Ke Huang; Fu-Lin Jiang; Jian Wang; Qi-Hong Yu; Kai-Feng Qiu; Min Huang; Jun-Yan Wu; Dun-Hua Zhou; Guo-Ping Zhong; Xiao-Xia Yu
Journal:  Front Pharmacol       Date:  2022-07-06       Impact factor: 5.988

2.  Diltiazem on tacrolimus exposure and dose sparing in Chinese pediatric primary nephrotic syndrome: impact of CYP3A4, CYP3A5, ABCB1, and SLCO1B3 polymorphisms.

Authors:  Junyan Wang; Lingfei Huang; Peng Gao; Yan Hu; Yinghua Ni; Zhengyi Zhu; Liwen Zhang; Jufei Yang; Huifen Zhang; Luo Fang
Journal:  Eur J Clin Pharmacol       Date:  2020-08-15       Impact factor: 2.953

3.  Population Pharmacokinetics and Dosage Optimization of Teicoplanin in Children With Different Renal Functions.

Authors:  Liuliu Gao; Hua Xu; Qi Ye; Sichan Li; Jun Wang; Yan Mei; Changhe Niu; Ting Kang; Chen Chen; Yang Wang
Journal:  Front Pharmacol       Date:  2020-05-05       Impact factor: 5.810

4.  Impact of Sampling Time Variability on Tacrolimus Dosage Regimen in Pediatric Primary Nephrotic Syndrome: Single-Center, Prospective, Observational Study.

Authors:  Lingfei Huang; Junyan Wang; Jufei Yang; Huifen Zhang; Yan Hu; Jing Miao; Jianhua Mao; Luo Fang
Journal:  Front Pharmacol       Date:  2022-01-07       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.